The Oxford / AstraZeneca stable cove shield still contains more than 90 percent of the 12.7676 billion CVD-19 vaccines administered across the country, according to official data to date.
Of these, 15 states and union territories have given only Kovishield, creating the Pune-based Serum Institute in India. Other vaccines operated in India are the indigenous Kovacin of India Biotech in Hyderabad.
According to the government’s CO-Win portal, of the 127,05,670 Covid-19 vaccine jobs operated so far, 11,60,65,107 Covishields and 1,15,40,763 Covacsins are described.
In addition, about 15 states and union territories, including Goa, Chandigarh and Jammu and Kashmir, have operated Covishield only for its beneficiaries.
Experts say that Covishield is being produced on a much larger scale than Covacin which is why its availability is higher.
Dr Samiran Panda, head of epidemiology and communicable diseases at the Indian Council of Medical Research, said production of covacin would be increased soon.
“Following which, vaccine production capacity will increase significantly,” he said.
Capacity has been increased across multiple facilities in Hyderabad and Bangalore, to deliver about 70,000 million doses per year, India Biotech said on Tuesday.
The Department of Biotechnology is providing financial support in the form of grants for vaccine production facilities to increase increased production capacity.
“The current production capacity of the domestically developed covacin vaccine will be doubled by May 2020 and then increased almost 7-fold by July-August 2021, increasing production from 10 million vaccine doses in April, 2021 to 60-70 million.” The dose will be given in July-August, “the Ministry of Science and Technology said in a statement on Monday.
India has urgently approved the use of Kovacin and Kovishield, after which the vaccination campaign began in the country on 1 16 January.
Prime Minister Narendra Modi and External Affairs Minister S Jaishankar were among the co-vaccine operators of India Biotech.